立体定向体部放疗联合多药化疗后术中放疗治疗局限性胰腺腺癌的安全性研究:Ⅰ期试验研究方案
该Ⅰ期试验方案拟入组非转移性胰头或胰颈胰腺腺癌患者,在多药新辅助化疗和立体定向体部放疗(40 Gy/5次)后,于Whipple术中针对Triangle Volume行术中放疗(15 Gy/1次)。主要终点为术中放疗后急性(<90天)毒性(Clavien-Dindo分级),次要终点包括晚期毒性、总生存、局部无进展生存、无远处转移生存和无进展生存。
要点
- 新辅助化疗和SBRT(40 Gy/5次)后,Whipple术中针对Triangle Volume行IORT 15 Gy/1次。
- 主要终点为IORT后急性(<90天)毒性,采用Clavien-Dindo分级评估。
- 若结果示安全可行,作者认为值得开展Ⅱ期试验评估疗效。
核心结论
- 若结果显示新辅助化疗和SBRT后针对Triangle Volume行消融剂量IORT安全可行,作者认为值得开展Ⅱ期试验评估该方法的疗效。
研究设计与样本
- Ⅰ期试验方案,拟入组非转移性、肿瘤位于胰头或胰颈的胰腺腺癌患者。
- 患者接受多药新辅助化疗后行SBRT(40 Gy/5次),随后在Whipple术中针对Triangle Volume行IORT(15 Gy/1次)。
- 主要终点为IORT后急性(<90天)毒性,采用Clavien-Dindo分级评估;次要终点包括晚期(>90天)毒性、总生存、局部无进展生存、无远处转移生存和无进展生存。
- 该研究于2021年12月2日在ClinicalTrials.gov注册(NCT05141513)。
主要发现
- 原文为研究方案,未报告入组患者数或疗效/毒性结果。
- 背景指出高达40%的患者可能以局部区域病变为首发失败部位。
- 背景指出既往IORT研究未使用消融剂量(BED10 > 100 Gy)。
- 本研究中心近期分析提示几乎所有局部失败发生于Triangle Volume。
关键数值与推荐
- SBRT剂量为40 Gy/5次。
- IORT剂量为15 Gy/1次,照射Triangle Volume。
- 消融剂量定义为BED10 > 100 Gy。
- 主要终点急性毒性时间窗为<90天,晚期毒性时间窗为>90天,均采用Clavien-Dindo分级。
临床怎么用
- 原文为研究方案,未据此给出临床推荐。
局限性
- 原文为Ⅰ期试验方案,尚未报告安全性或疗效结果。
- 作者指出既往IORT研究未使用消融剂量(BED10 > 100 Gy)。
- 作者指出在该背景下最佳放疗靶区体积尚不明确。
- 作者指出若结果安全可行,值得进一步开展Ⅱ期试验评估疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Localized pancreatic adenocarcinoma carries a poor prognosis even after aggressive therapy. Up to 40% of patients may develop locoregional disease as the first site of failure. As such, there may be a role for intensification of local therapy such as radiation therapy. Radiation dose escalation for pancreatic cancer is limited by proximity of the tumor to the duodenum. However, the duodenum is removed during Whipple procedure, allowing the opportunity to dose escalate with intraoperative radiation therapy (IORT). Although prior studies have shown potential benefit of IORT in pancreatic cancer, these studies did not utilize ablative doses (biologically effective dose [BED10] > 100 Gy). Furthermore, the optimal radiation target volume in this setting is unclear. There has been increased interest in a "Triangle Volume" (TV), bordered by the celiac axis, superior mesenteric artery, common hepatic artery, portal vein, and superior mesenteric vein. Dissection of this area, has been advocated for by surgeons from Heidelberg as it contains extra-pancreatic perineural and lymphatic tracts, which may harbor microscopic disease at risk of mediating local failure. Interestingly, a recent analysis from our institution indicated that nearly all local failures occur in the TV. Therefore, the purpose of this protocol is to evaluate the safety of delivering an ablative radiation dose to the TV with IORT following neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT). METHODS: Patients with non-metastatic pancreatic adenocarcinoma centered in the head or neck of the pancreas will be enrolled. Following treatment with multi-agent neoadjuvant chemotherapy, patients will undergo SBRT (40 Gy/5 fractions) followed by IORT (15 Gy/1 fraction) to the TV during the Whipple procedure. The primary objective is acute (< 90 days) toxicity after IORT measured by Clavien-Dindo classification. Secondary objectives include late (> 90 days) toxicity after IORT measured by Clavien-Dindo classification, overall survival, local progression-free survival, distant metastasis-free survival, and progression-free survival. DISCUSSION: If the results show that delivering an ablative radiation dose to the TV with IORT after neoadjuvant chemotherapy and SBRT is safe and feasible, it warrants further investigation in a phase II trial to evaluate efficacy of this approach. Trial Registration This study was registered at ClinicalTrials.gov on 12/2/2021 (NCT05141513). https://clinicaltrials.gov/ct2/show/NCT05141513.
引用
- Reddy AV, Hill CS, Zheng L, et al. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial. Radiat Oncol. 2022. PMID: 36307845. doi:10.1186/s13014-022-02145-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。